

KING & SPALDING

King & Spalding LLP
1700 Pennsylvania Avenue, N.W.
Washington, DC 20006-4706
www.kslaw.com

Theodore M. Hester
Direct Dial: (202) 626-2901
Direct Fax: (202) 626-3737
thester@kslaw.com

April 28, 2008

BY HAND DELIVERY
ATTN: Mr. John Sopko

The Honorable John D. Dingell
Chairman, Committee on Energy and Commerce
The Honorable Bart Stupak
Chairman, Subcommittee on Oversight
and Investigations
House of Representatives
Ford House Office Building, Room 316
Washington, D.C. 20515-6115

PFIZER, INC. CONFIDENTIAL
TREATMENT REQUESTED

Dear Chairmen Dingell and Stupak:

This letter is submitted on behalf of Pfizer, Inc. ("Pfizer"), in response to your letter, dated January 7, 2008, requesting that Pfizer provide the Committee on Energy and Commerce ("Committee") with records pursuant to the Committee's investigation regarding "the use of celebrity endorsements of prescription medications in direct-to-consumer advertising."

As set forth in our letter to the Committee, dated January 23, 2008, and fully incorporated herewith by reference, Pfizer respectfully requests that the Committee afford these records the maximum protection available to information provided to the Committee. The intentional or inadvertent disclosure of information that Pfizer has expressly designated as confidential, trade secret, and proprietary would likely cause substantial competitive harm to Pfizer. We also respectfully request advance notice of any contemplated disclosure of Pfizer's confidential, trade secret, and proprietary information, and a reasonable opportunity to object. Please direct any such notice to me at the above address.

Today, Pfizer is supplementing its January 23, February 13, and March 10, 2008 productions with additional records regarding Lipitor® ("*Lipitor*") advertisements involving Dr. Robert Jarvik, M.D, as a spokesperson. Pursuant to discussions with the Committee on February 5, we agreed that Pfizer would produce records on a rolling basis. We are providing records responsive to your requests in electronic format (produced on 5 DVDs, in PDF searchable format, numbered PFE-000047638 through PFE-000300391).

The Honorable John D. Dingell
The Honorable Bart Stupak
April 28, 2008
Page 2

This letter and the information and records enclosed contain or constitute confidential, trade secret, and proprietary information of Pfizer provided to the Committee pursuant to your requests. Accordingly, Pfizer has marked all records produced today with the legend "PFIZER, INC. CONFIDENTIAL TREATMENT REQUESTED." In responding to these requests, Pfizer has used its best efforts to be as accurate and responsive as possible within the time frame set by the Committee for responses and based on Pfizer's understanding of the terms used in the request. The representations herein are based on Pfizer's current information and belief.

In providing information and records in response to the Committee's requests, Pfizer does not waive, nor does it intend to waive, any of its rights or privileges with respect to this inquiry by the Committee, including any applicable attorney-client, work product or other evidentiary privilege, or any objection to the letter request from the Committee.

If you have any questions regarding this matter, or need additional information, please do not hesitate to call me at (202) 626-2901.

Sincerely,

A handwritten signature in black ink, appearing to read 'T. Hester', with a large, stylized initial 'T'.

Theodore M. Hester

cc: The Honorable Joe Barton, Ranking Member
Committee on Energy and Commerce

The Honorable John Shimkus, Ranking Member
Subcommittee on Oversight and Investigations